Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Allogeneic NK Cells + Chemotherapy for Relapsed/Refractory Pediatric Solid Tumors
NCT03420963Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2018
- Primary completion
- Feb 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cord blood-derived expanded allogeneic natural killer cells in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 30 days and Maximum tolerated dose and/or recommended phase 2 dose at 30 days. Started Aug 2018; status: terminated.
02
Drugs
cord blood-derived expanded allogeneic natural killer cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03420963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420963.